Yes, domperidone works through a fundamentally different mechanism than ondansetron.
Ondansetron is a selective 5-HT₃ (serotonin) receptor antagonist, while domperidone is a D₂ dopamine receptor antagonist—these are completely different pharmacological pathways for controlling nausea and vomiting. 1, 2
Mechanism of Action Differences
Ondansetron's mechanism:
- Blocks serotonin 5-HT₃ receptors both peripherally (on vagal nerve terminals) and centrally (in the chemoreceptor trigger zone)
- Works by preventing serotonin released from enterochromaffin cells during chemotherapy or gastroenteritis from triggering the vomiting reflex
- Does NOT act on dopamine receptors 1
Domperidone's mechanism:
- Blocks D₂ dopamine receptors at the cellular level
- Critically, domperidone does NOT readily cross the blood-brain barrier, unlike other dopamine antagonists
- Has prokinetic effects (enhances gastric motility), which ondansetron lacks 2, 3
Clinical Efficacy Comparison
For pediatric acute gastroenteritis, ondansetron is definitively superior to domperidone:
- Ondansetron reduces the need for IV rehydration by over 50% compared to both domperidone (RR 0.47) and placebo (RR 0.41) 4
- At 24 hours, ondansetron achieves 92.5% vomiting cessation versus 82.5% for domperidone 5
- Fewer children require additional antiemetic doses with ondansetron (RR 0.50) 6
- Multiple meta-analyses confirm ondansetron's superiority for gastroenteritis-related vomiting 7, 6
Important Clinical Distinctions
Motility effects:
- Ondansetron slows colonic transit but has no effect on gastric motility or esophageal function 1
- Domperidone is a prokinetic agent that enhances gastric emptying 3
Blood-brain barrier penetration:
- Ondansetron crosses the blood-brain barrier and acts centrally
- Domperidone has minimal CNS penetration, resulting in lower risk of extrapyramidal side effects 2, 3
Side effect profiles:
- Ondansetron: QTc prolongation risk (dose-dependent), constipation
- Domperidone: Lower extrapyramidal risk than other dopamine antagonists, but still carries QTc prolongation risk and cardiac concerns 3
Context-Specific Use
For chemotherapy-induced nausea/vomiting: Ondansetron is the guideline-recommended 5-HT₃ antagonist as part of standard antiemetic regimens for moderate to high emetogenic chemotherapy 8, 9. Domperidone is not included in these guidelines.
For Parkinson's disease with apomorphine: Domperidone is superior to ondansetron, as ondansetron's serotonin blockade doesn't address dopamine-mediated nausea 10.
The bottom line: these drugs target entirely different neurotransmitter systems, making them mechanistically distinct antiemetics with different clinical applications and efficacy profiles.